enGene Holdings Inc.

NASDAQ:ENGN

Biotechnology

Healthcare
$1.85 -1.15%

-$0.02 today

Market cap
$123.98M
Beta
-0.29
P/E (TTM)
-1.8
EPS (TTM)
-$0.95
52W Low $1.40High $12.25

Volume 2.81M

Average 1.58M

ENGN Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

enGene Holdings Inc.NASDAQ: ENGN

Cost of Revenue · Q2 FY2026 · quarter ended Apr 2026

Cost of revenue remains negative

Q2 FY2026 cost of revenue was $180K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $369K.

Context

  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $180K or moves back toward the trailing-twelve-month quarterly average of $92.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
$180K-4.8% QoQ
Last fiscal yearOct 2025
$0— YoY
LTMApr 2026
$369K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How ENGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
ENGN Competitors
Cost of Revenue for ENGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$102.11M USD-27.2%-9.9%47.5%
ALTAltimmune, Inc.LTM Mar 2026$14.98M USD——41619.4%
DBVTDBV Technologies S.A.LTM Mar 2026$13.12M USD+215.9%-4.5%—
CLLSCellectis S.A.LTM Mar 2026$12.33M USD+39.3%+4.9%18.1%
ANNXAnnexon, Inc.LTM Mar 2026$1.9M USD———
KRROKorro Bio, Inc.LTM Mar 2026$1.03M USD——26.8%
ENGNenGene Holdings Inc.LTM Apr 2026$369K USD———
SLNSilence Therapeutics plcLTM Mar 2026$309.37K USD—-73.0%33.6%
ANROAlto Neuroscience, Inc.LTM Mar 2026$284K USD+67.1%+24.6%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD———
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF——0.0%
Peer median (excluding ENGN) —+53.2%-4.5%30.2%

Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development12.46M15.47M16.46M38.32M94.48M
Selling, General & Admin3.16M3.26M8.47M23.98M28.69M
Operating Expenses15.87M19.43M26.06M62.3M123.17M
Depreciation & Amortization272K238K175K323K509K
EBITDA(18.15M)(22.78M)(94.77M)(52.04M)(113.8M)
EBITDA Margin—————
Operating Income(15.87M)(19.43M)(26.06M)(62.3M)(123.17M)
Operating Margin—————
Interest Income25K129K1.12M10.41M9.43M
Interest Expense5.02M1.42M4.95M2.8M2.99M
Other Income / Expenses(7.57M)(5.01M)(73.84M)7.14M5.86M
Income Before Tax(23.44M)(24.44M)(99.9M)(55.16M)(117.3M)
Pre-Tax Margin—————
Income Tax Expense022K17K(19K)0
Net Income(23.44M)(24.46M)(99.92M)(55.14M)(117.3M)
Net Margin—————
EPS (Basic)(0.01)0.00(4.24)(1.46)(2.29)
EPS (Diluted)(0.01)0.00(4.24)(1.46)(2.29)
Weighted Avg Shares15.81M15.81M23.56M44.64M51.12M
Weighted Avg Shares (Diluted)15.81M15.81M23.56M44.64M51.12M

enGene Holdings Inc.

NASDAQ:ENGN

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.